Stockscreener 앱 받기
5.23
0.19%
0.01
시간 외 거래:
5.00
-0.23
-4.40%
전일 마감가:
$5.22
열려 있는:
$5.09
하루 거래량:
3.47M
Relative Volume:
2.36
시가총액:
$557.48M
수익:
-
순이익/손실:
$-134.24M
주가수익비율:
-2.6414
EPS:
-1.98
순현금흐름:
$-121.34M
1주 성능:
+17.79%
1개월 성능:
+1.36%
6개월 성능:
+0.58%
1년 성능:
+81.60%
1일 변동 폭
$5.05
$5.315
1주일 범위
$4.685
$5.315
52주 변동 폭
$3.27
$8.40
아넥손 Stock (ANNX) Company Profile
명칭
Annexon Inc
전화
(650)-822-5500
주소
1400 SIERRA POINT PARKWAY, BRISBANE
ANNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
5.23 | 557.48M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
아넥손 Stock (ANNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-30 | 개시 | Wells Fargo | Overweight |
| 2023-05-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-05-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | BTIG Research | Buy |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-09-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
모두보기
아넥손 주식(ANNX)의 최신 뉴스
Annexon (NASDAQ:ANNX) Shares Down 3.8%Time to Sell? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Annexon (NASDAQ:ANNX) - Defense World
New Data Supports BLA Package - Streetwise Reports
Annexon (NASDAQ:ANNX) Given Buy Rating at HC Wainwright - MarketBeat
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Awards Major Stock Options Package to New Hires in Strategic Talent Acquisition Move - StockTitan
Annexon shares rise on positive Guillain-Barré study results - Investing.com
Annexon (NASDAQ:ANNX) Shares Gap UpWhat's Next? - MarketBeat
Annexon shares rise on positive Guillain-Barré study results By Investing.com - Investing.com Australia
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) - The Manila Times
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 - The Bakersfield Californian
Charles Schwab Investment Management Inc. Boosts Stock Position in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
The Manufacturers Life Insurance Company Buys 2,450 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Intech Investment Management LLC Purchases Shares of 26,013 Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Stock Holdings Raised by Fmr LLC - Defense World
Fmr LLC Has $50.69 Million Holdings in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Holdings Lowered by Point72 Asset Management L.P. - MarketBeat
Readystate Asset Management LP Reduces Stake in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon to Present Phase 2 ARCHER Data on Protection of - GlobeNewswire
Annexon's ANX007 Shows Breakthrough Vision Protection in Geographic Atrophy Clinical Data - StockTitan
328,698 Shares in Annexon, Inc. (NASDAQ:ANNX) Purchased by Walleye Capital LLC - MarketBeat
Insider Buying: William Carson Acquires Additional Shares of Ann - GuruFocus.com
Annexon director Carson William H. buys $17,056 in stock By Investing.com - Investing.com Nigeria
Annexon director Carson William H. buys $17,056 in stock - Investing.com
Annexon, Inc. (NASDAQ:ANNX) Receives $15.80 Consensus PT from Analysts - MarketBeat
1,433,155 Shares in Annexon, Inc. (NASDAQ:ANNX) Purchased by Sio Capital Management LLC - MarketBeat
Massachusetts Financial Services Co. MA Boosts Holdings in Annexon, Inc. (NASDAQ:ANNX) - MarketBeat
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by GSA Capital Partners LLP - Defense World
Trial results for novel CAD treatment now expected early 2025 - Cold Agglutinin News
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - PharmaVoice
Insiders Enjoy US$903k Return After Buying Annexon Stock - Simply Wall St
HC Wainwright Has Negative View of Annexon FY2027 Earnings - MarketBeat
Annexon (NASDAQ:ANNX) Earns “Buy” Rating from HC Wainwright - Defense World
Annexon (NASDAQ:ANNX) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
Financial Contrast: Annexon (NASDAQ:ANNX) & Acasti Pharma (NASDAQ:ACST) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Short Interest Down 12.9% in October - MarketBeat
Annexon Grants 495,000 Stock Options to New Employees in Talent Acquisition Push | ANNX Stock News - StockTitan
Annexon's (ANNX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Annexon's (ANNX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Annexon (NASDAQ:ANNX) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Logos Global Management LP Adjusts Stake in Annexon Inc - GuruFocus.com
Annexon Biosciences Reports Q3 Financial Results - TipRanks
Annexon Inc (ANNX) Quarterly 10-Q Report - Quartzy
Annexon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones - GlobeNewswire
Annexon Biosciences to Present at the Jefferies London Healthcare Conference - GlobeNewswire
FMR LLC's Strategic Acquisition of Annexon Inc Shares - GuruFocus.com
Creative Planning Has $206,000 Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Analysts Set Annexon, Inc. (NASDAQ:ANNX) Price Target at $15.80 - MarketBeat
JP Morgan Upgrades Annexon (ANNX) - MSN
Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ - GlobeNewswire
아넥손 (ANNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):